Crinetics | News & Events

PRESS RELEASES

Press Release | May 12, 2022

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Press Release | May 10, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Press Release | April 18, 2022

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

Press Release | April 13, 2022

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

Press Release | April 11, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Press Release | March 30, 2022

Crinetics Reports Positive Top-Line Results from CRN04777 Phase 1 MAD Cohorts

Press Release | March 30, 2022

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

Press Release | March 21, 2022

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

Press Release | March 14, 2022

Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors

Press Release | March 10, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 / 24

Transforming Endocrine Disease Treatment

Be the first to know about the advances we're making in endocrine-rooted care.

Email Signup